NLC Pharma (3CL Protease Biology Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

NLC Pharma (3CL Protease Biology Assets) General Information

Description

Rights of therapeutics, diagnostics and dietary supplements to treat the acute respiratory syndrome.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Tel Aviv
  • Israel
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Todos Medical
Corporate Office
  • Tel Aviv
  • Israel

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NLC Pharma (3CL Protease Biology Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NLC Pharma (3CL Protease Biology Assets)‘s full profile, request access.

Request a free trial

NLC Pharma (3CL Protease Biology Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NLC Pharma (3CL Protease Biology Assets)‘s full profile, request access.

Request a free trial

NLC Pharma (3CL Protease Biology Assets) FAQs

  • Where is NLC Pharma (3CL Protease Biology Assets) headquartered?

    NLC Pharma (3CL Protease Biology Assets) is headquartered in Tel Aviv, Israel.

  • What industry is NLC Pharma (3CL Protease Biology Assets) in?

    NLC Pharma (3CL Protease Biology Assets)’s primary industry is Buildings and Property.

  • Is NLC Pharma (3CL Protease Biology Assets) a private or public company?

    NLC Pharma (3CL Protease Biology Assets) is a Private company.

  • What is the current valuation of NLC Pharma (3CL Protease Biology Assets)?

    The current valuation of NLC Pharma (3CL Protease Biology Assets) is 00000.

  • What is NLC Pharma (3CL Protease Biology Assets)’s current revenue?

    The current revenue for NLC Pharma (3CL Protease Biology Assets) is 000000.

  • Who are NLC Pharma (3CL Protease Biology Assets)’s investors?

    NLC Pharma has invested in NLC Pharma (3CL Protease Biology Assets).

  • When was NLC Pharma (3CL Protease Biology Assets) acquired?

    NLC Pharma (3CL Protease Biology Assets) was acquired on 16-Mar-2022.

  • Who acquired NLC Pharma (3CL Protease Biology Assets)?

    NLC Pharma (3CL Protease Biology Assets) was acquired by Todos Medical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »